Advertisement

Molecular Biology Reports

, Volume 39, Issue 9, pp 8723–8732 | Cite as

MTHFR C677T and A1298C polymorphisms and cervical carcinoma susceptibility: meta-analyses based on 4421 individuals

  • Wen-Lei Zhuo
  • Liang Zhang
  • Jun-Jun Ling
  • Yi Zhu
  • Zheng-Tang Chen
Article

Abstract

MTHFR polymorphisms have been implicated as risk factors for several cancers. Studies have conducted on the associations of MTHFR polymorphisms with cervical carcinoma risk and have generated inconclusive results. The aim of the present study was to increase power demonstrating the possible relations. Meta-analyses examining the association between MTHFR C677T and A1298C polymorphisms and cervical carcinoma risk were performed. Separate analyses on ethnicity and source of controls were also implemented. Eligible studies were identified for the period up to Dec 2011. Eleven case–control studies containing 1859 cases and 2562 controls regarding MTHFR C677T polymorphisms were selected, of which four studies containing 461 cases and 832 controls described A1298C polymorphisms. For the overall data, no associations of MTHFR C677T polymorphisms with cervical carcinoma were observed (TT vs CC: OR = 1.07; 95 %CI = 0.73–1.58; dominant model: OR = 0.89; 95 %CI = 0.66–1.18; recessive model: OR = 1.13; 95 %CI = 0.84–1.52). In the subgroup analysis by ethnicity, MTHFR 677T allele was associated with decreased cervical cancer susceptibility among Caucasians (TT vs CC: OR = 0.65; 95 %CI = 0.45–0.93; dominant model: OR = 0.70; 95 %CI = 0.58–0.86) but not Asians. As for A1298C polymorphism, no marked associations of A1298C genetic variation with cervical cancer risk were observed (CC vs AA: OR = 1.01; 95 %CI = 0.60–1.73; dominant model: OR = 1.17; 95 %CI = 0.91–1.49; recessive model: OR = 0.99; 95 %CI = 0.60–1.63). Collectively, the results of the present study suggest that MTHFR 677T allele might play a preventive role for cervical carcinoma among Caucasians. A1298C polymorphisms might exert little effect on cervical cancerigenesis.

Keywords

MTHFR Cervical neoplasm Susceptibility Meta-analysis Polymorphism 

Notes

Conflict of interest

None declared.

References

  1. 1.
    Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90CrossRefPubMedGoogle Scholar
  2. 2.
    Gadducci A, Barsotti C, Cosio S, Domenici L, Riccardo Genazzani A (2011) Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature. Gynecol Endocrinol 27:597–604CrossRefPubMedGoogle Scholar
  3. 3.
    Wattleworth R (2011) Human papillomavirus infection and the links to penile and cervical cancer. J Am Osteopath Assoc 111:S3–10PubMedGoogle Scholar
  4. 4.
    Gao LB, Pan XM, Li LJ et al (2011) Null genotypes of GSTM1 and GSTT1 contribute to risk of cervical neoplasia: an evidence-based meta-analysis. PLoS One 6:e20157CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Ding B, Fu S, Wang M et al (2011) Tumor Necrosis Factor alpha −308 G>A polymorphisms and cervical cancer risk: a meta-analysis. Int J Gynecol Cancer 22(2):213–219Google Scholar
  6. 6.
    Li Y, Liu F, Tan S, Li S (2011) P21 Ser31Arg polymorphism and cervical cancer risk: a meta-analysis. Int J Gynecol Cancer 21:445–451CrossRefPubMedGoogle Scholar
  7. 7.
    Klug SJ, Ressing M, Koenig J et al (2009) TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol 10:772–784CrossRefPubMedGoogle Scholar
  8. 8.
    Ni J, Wang M, Fu S et al (2011) CCND1 G870A polymorphism and cervical cancer risk: a case-control study and meta-analysis. J Cancer Res Clin Oncol 137:489–494CrossRefPubMedGoogle Scholar
  9. 9.
    James SJ, Pogribny IP, Pogribna M et al (2003) Mechanisms of DNA damage, DNA hypomethylation, and tumor progression in the folate/methyl-deficient rat model of hepatocarcinogenesis. J Nutr 133:3740S–3747SPubMedGoogle Scholar
  10. 10.
    Duthie SJ, Narayanan S, Sharp L et al (2004) Folate, DNA stability and colo-rectal neoplasia. Proc Nutr Soc 63:571–578CrossRefPubMedGoogle Scholar
  11. 11.
    Kim YI (2009) Role of the MTHFR polymorphisms in cancer risk modification and treatment. Future Oncol 5:523–542CrossRefPubMedGoogle Scholar
  12. 12.
    Toffoli G, De Mattia E (2008) Pharmacogenetic relevance of MTHFR polymorphisms. Pharmacogenomics 9:1195–1206CrossRefPubMedGoogle Scholar
  13. 13.
    Rozen R (1997) Genetic predisposition to hyperhomocysteinemia: deficiency of methylenetetrahydrofolate reductase (MTHFR). Thromb Haemost 78:523–526PubMedGoogle Scholar
  14. 14.
    De Mattia E, Toffoli G (2009) C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur J Cancer 45:1333–1351CrossRefPubMedGoogle Scholar
  15. 15.
    Munafo MR, Clark TG, Flint J (2004) Assessing publication bias in genetic association studies: evidence from a recent meta-analysis. Psychiatry Res 129:39–44CrossRefPubMedGoogle Scholar
  16. 16.
    Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Zoodsma M, Nolte IM, Te Meerman GJ, De Vries EG, Van der Zee AG (2005) HLA genes and other candidate genes involved in susceptibility for (pre)neoplastic cervical disease. Int J Oncol 26:769–784PubMedGoogle Scholar
  18. 18.
    Powers HJ (2005) Interaction among folate, riboflavin, genotype, and cancer, with reference to colorectal and cervical cancer. J Nutr 135:2960S–2966SPubMedGoogle Scholar
  19. 19.
    Piyathilake CJ, Macaluso M, Johanning GL et al (2000) Methylenetetrahydrofolate reductase (MTHFR) polymorphism increases the risk of cervical intraepithelial neoplasia. Anticancer Res 20:1751–1757PubMedGoogle Scholar
  20. 20.
    Goodman MT, McDuffie K, Hernandez B et al (2001) Association of methylenetetrahydrofolate reductase polymorphism C677T and dietary folate with the risk of cervical dysplasia. Cancer Epidemiol Biomarkers Prev 10:1275–1280PubMedGoogle Scholar
  21. 21.
    Agodi A, Barchitta M, Cipresso R et al (2010) Distribution of p53, GST, and MTHFR polymorphisms and risk of cervical intraepithelial lesions in sicily. Int J Gynecol Cancer 20:141–146CrossRefPubMedGoogle Scholar
  22. 22.
    Piyathilake CJ, Azrad M, Macaluso M et al (2007) Protective association of MTHFR polymorphism on cervical intraepithelial neoplasia is modified by riboflavin status. Nutrition 23:229–235CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Kim K, Kang SB, Chung HH et al (2008) XRCC1 Arginine194Tryptophan and GGH-401Cytosine/Thymine polymorphisms are associated with response to platinum-based neoadjuvant chemotherapy in cervical cancer. Gynecol Oncol 111:509–515CrossRefPubMedGoogle Scholar
  24. 24.
    Gerhard DS, Nguyen LT, Zhang ZY et al (2003) A relationship between methylenetetrahydrofolate reductase variants and the development of invasive cervical cancer. Gynecol Oncol 90:560–565CrossRefPubMedGoogle Scholar
  25. 25.
    Rao GG, Kurien A, Gossett D et al (2006) A case-control study of methylenetetrahydrofolate reductase polymorphisms in cervical carcinogenesis. Gynecol Oncol 101:250–254CrossRefPubMedGoogle Scholar
  26. 26.
    Nandan NK, Wajid S, Biswas S et al (2008) Allelic variations in 5, 10-methylenetetrahydrofolate reductase gene and susceptibility to cervical cancer in Indian women. Drug Metab Lett 2:18–22CrossRefPubMedGoogle Scholar
  27. 27.
    Yang F, Zhou Y, Jiang Y, Fan Y, Li J (2011) Study on the correlation between polymorphism of MTHFR gene and pathogenesis of cervical cancer. Maternal and Child Health Care of China 26:4087–4089Google Scholar
  28. 28.
    Tong SY, Lee JM, Song ES et al (2010) The effects of polymorphisms in methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTR), and methionine synthase reductase (MTRR) on the risk of cervical intraepithelial neoplasia and cervical cancer in Korean women. Cancer Causes Control 21:23–30CrossRefPubMedGoogle Scholar
  29. 29.
    Tong SY, Kim MK, Lee JK et al (2011) Common polymorphisms in methylenetetrahydrofolate reductase gene are associated with risks of cervical intraepithelial neoplasia and cervical cancer in women with low serum folate and vitamin B12. Cancer Causes Control 22:63–72CrossRefPubMedGoogle Scholar
  30. 30.
    Lambropoulos AF, Agorastos T, Foka ZJ et al (2003) Methylenetetrahydrofolate reductase polymorphism C677T is not associated to the risk of cervical dysplasia. Cancer Lett 191:187–191CrossRefPubMedGoogle Scholar
  31. 31.
    Sull JW, Jee SH, Yi S et al (2004) The effect of methylenetetrahydrofolate reductase polymorphism C677T on cervical cancer in Korean women. Gynecol Oncol 95:557–563CrossRefPubMedGoogle Scholar
  32. 32.
    Kang S, Kim JW, Kang GH et al (2005) Polymorphism in folate- and methionine-metabolizing enzyme and aberrant CpG island hypermethylation in uterine cervical cancer. Gynecol Oncol 96:173–180CrossRefPubMedGoogle Scholar
  33. 33.
    Zoodsma M, Nolte IM, Schipper M et al (2005) Methylenetetrahydrofolate reductase (MTHFR) and susceptibility for (pre)neoplastic cervical disease. Hum Genet 116:247–254CrossRefPubMedGoogle Scholar
  34. 34.
    Delgado-Enciso I, Martinez-Garza SG, Rojas-Martinez A et al (2006) The effect of MTHFR polymorphisms, pregnancy and first intercourse on cervical cancer in a population from the Northeastern Mexico. Rev Invest Clin 58:462–469PubMedGoogle Scholar
  35. 35.
    Ma X, Wang J, Zhou Q et al (2006) Relationship between methylenetetrahydrofolate reductase polymorphism and cervical cancer susceptibility. Chin J Public Health 22:1427–1428Google Scholar
  36. 36.
    Shekari M, Sobti RC, Kordi Tamandani DM, Suri V (2008) Impact of methylenetetrahydrofolate reductase (MTHFR) codon (677) and methionine synthase (MS) codon (2756) on risk of cervical carcinogenesis in North Indian population. Arch Gynecol Obstet 278:517–524CrossRefPubMedGoogle Scholar
  37. 37.
    Kohaar I, Kumar J, Thakur N et al (2010) Homocysteine levels are associated with cervical cancer independent of methylene tetrahydrofolate reductase gene (MTHFR) polymorphisms in Indian population. Biomarkers 15:61–68CrossRefPubMedGoogle Scholar
  38. 38.
    Mostowska A, Myka M, Lianeri M, Roszak A, Jagodzinski PP (2011) Folate and choline metabolism gene variants and development of uterine cervical carcinoma. Clin Biochem 44:596–600CrossRefPubMedGoogle Scholar
  39. 39.
    Prasad VV, Wilkhoo H (2011) Association of the functional polymorphism C677T in the methylenetetrahydrofolate reductase gene with colorectal, thyroid, breast, ovarian, and cervical cancers. Onkologie 34:422–426CrossRefPubMedGoogle Scholar
  40. 40.
    Tobias A (1999) Assessing the influence of a single study in the meta-analysis estimate. Stata Techn Bull 8:15–17Google Scholar
  41. 41.
    Rossmanith P, Mester P, Fruhwirth K, Fuchs S, Wagner M (2011) Proof of concept for recombinant cellular controls in quantitative molecular pathogen detection. Appl Environ Microbiol 77:2531–2533CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Qi X, Ma X, Yang X et al (2010) Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk: a meta-analysis from 41 studies with 16,480 cases and 22,388 controls. Breast Cancer Res Treat 123:499–506CrossRefPubMedGoogle Scholar
  43. 43.
    Mazaki T, Masuda H, Takayama T (2011) Polymorphisms and pancreatic cancer risk: a meta-analysis. Eur J Cancer Prev 20:169–183CrossRefPubMedGoogle Scholar
  44. 44.
    Dong X, Wu J, Liang P et al (2010) Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and gastric cancer: a meta-analysis. Arch Med Res 41:125–133CrossRefPubMedGoogle Scholar
  45. 45.
    Jin F, Qu LS, Shen XZ (2009) Association between the methylenetetrahydrofolate reductase C677T polymorphism and hepatocellular carcinoma risk: a meta-analysis. Diagn Pathol 4:39CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Bai JL, Zheng MH, Xia X et al (2009) MTHFR C677T polymorphism contributes to prostate cancer risk among Caucasians: a meta-analysis of 3511 cases and 2762 controls. Eur J Cancer 45:1443–1449CrossRefPubMedGoogle Scholar
  47. 47.
    Taioli E, Garza MA, Ahn YO et al (2009) Meta- and pooled analyses of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and colorectal cancer: a HuGE-GSEC review. Am J Epidemiol 170:1207–1221CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Qiu LX, Zhang J, Li WH et al (2011) Lack of association between methylenetetrahydrofolate reductase gene A1298C polymorphism and breast cancer susceptibility. Mol Biol Rep 38:2295–2299CrossRefPubMedGoogle Scholar
  49. 49.
    Kim YI, Pogribny IP, Basnakian AG et al (1997) Folate deficiency in rats induces DNA strand breaks and hypomethylation within the p53 tumor suppressor gene. Am J Clin Nutr 65:46–52PubMedGoogle Scholar
  50. 50.
    Kamen B (1997) Folate and antifolate pharmacology. Semin Oncol 24:S18-30–S18-39Google Scholar
  51. 51.
    Novakovic P, Stempak JM, Sohn KJ, Kim YI (2006) Effects of folate deficiency on gene expression in the apoptosis and cancer pathways in colon cancer cells. Carcinogenesis 27:916–924CrossRefPubMedGoogle Scholar
  52. 52.
    Lee HY, Ju E, Vang PD, Lundquist M (2010) Breast and cervical cancer screening among Asian American women and Latinas: does race/ethnicity matter? J Womens Health (Larchmt) 19:1877–1884CrossRefGoogle Scholar
  53. 53.
    Coker AL, Eggleston KS, Du XL, Ramondetta L (2009) Ethnic disparities in cervical cancer survival among Medicare eligible women in a multiethnic population. Int J Gynecol Cancer 19:13–20CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  1. 1.Institute of Cancer, Xinqiao HospitalThird Military Medical UniversityChongqingChina
  2. 2.Department of Environmental Hygiene, College of Preventive MedicineThird Military Medical UniversityChongqingChina
  3. 3.Department of Otolaryngology, Southwest HospitalThird Military Medical UniversityChongqingChina
  4. 4.College of Food Science and Nutritional EngineeringChina Agriculture UniversityBeijingChina

Personalised recommendations